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Amyloid-b in mitochondrial disease:
mutation in a human metallopeptidase
links amyloidotic neurodegeneration with
mitochondrial processing
Veronika Boczonadi & Rita Horvath
There is increasing evidence that common
molecular pathways in neurons are
closely linked with mitochondrial function
and that mitochondrial dysfunction is
connected to various forms of neuro-
degenerative diseases. For instance,
mitochondria are involved in amyloid-b
(Ab) deposition in Alzheimer’s disease,
although the exact molecular pathways
remain largely unknown. Brunetti et al
(2015) in this issue of EMBO Molecular
Medicine provide a novel link between Ab
accumulation and mitochondria. A patho-
genic mutation in a Norwegian family
in the mitochondrial metallopeptidase
PITRM1 is found to underlie a novel mito-
chondrial neurodegenerative phenotype
associated with Ab accumulation.
See also: D Brunetti et al (March 2016)
N eurological symptoms are amongthe most frequent clinical manifesta-tions of primary mitochondrial
diseases (Chinnery, 2015). Certain neuronal
cell types are particularly sensitive to
mitochondrial dysfunction, exemplified by
manifestations such as Leigh syndrome,
optic atrophy, cerebellar ataxia, epilepsy and
peripheral neuropathy. It was originally
thought that a defect in energy production
caused by abnormal mitochondrial respira-
tory chain enzyme function is the major
pathogenic factor; however, it has become
evident that other roles of mitochondria
such as dynamics, trafficking, inter-orga-
nellar communication and mitochondrial
quality control are also important players in
neuronal dysfunction.
Our understanding of the role of mito-
chondria in neurons has been also recently
broadened through the discovery of mito-
chondrial dysfunction in various forms of
adult-onset neurodegeneration (Parkinson’s
disease, motor neuron disease, cerebellar
ataxias, spastic paraplegias), although the
exact neuronal death pathways still remain
largely unknown (Schon & Przedborski,
2011).
Although patients with neurodegenera-
tive diseases frequently present with
psychiatric symptoms and cognitive
dysfunction, these are not prominent
features or remain unnoticed in primary
mitochondrial conditions. Recent data in
Alzheimer’s disease (AD) suggested that
mitochondria are involved in amyloid-b
(Ab) deposition, which results in neuronal
toxicity.
AD is characterized by the accumulation
of extracellular plaques composed mainly of
Ab and of intracellular neurofibrillary
tangles composed of the microtubule-
associated protein tau. Other features
include aberrant phospholipid, cholesterol
and calcium metabolism and altered
mitochondrial function; the underlying mech-
anism(s) that might explain these observa-
tions are, however, currently unknown. It has
been shown that presenilin-1, presenilin-2,
and c-secretase, which process the amyloid
precursor protein (APP) to generate Ab, are
located predominantly in a specialized
subcompartment of the endoplasmic reticu-
lum (ER) that is physically and biochemi-
cally connected to mitochondria, referred to
as mitochondria-associated ER membranes
(MAM) (Schon & Area-Gomez, 2013). MAM
function and ER–mitochondrial connectivity
are significantly increased in AD, and it has
been hypothesized that AD might be an
ER–mitochondrial communication disorder
(the “MAM hypothesis”) (Schon & Area-
Gomez, 2013).
Progressive accumulation of Ab in mito-
chondria is associated with diminished
enzymatic activity of respiratory chain
complexes III and IV and a reduction in the
rate of oxygen consumption. The formation
of mitochondrial Ab plaques precedes the
characteristic extensive extracellular Ab
deposition and is evident before the onset of
clinical symptoms both in AD patients and
in APP transgenic mice, where they are
detected as early as 4 months of age
(Lustbader et al, 2004; Manczak et al, 2006).
Ab interacts with alcohol dehydrogenase
(ABAD) in the mitochondria and prevents
nicotinamide adenine dinucleotide (NAD)
binding, leading to exaggerated neuronal
oxidative stress and impaired memory.
These data suggest that the ABAD–Ab inter-
action may be a therapeutic target in AD
(Lustbader et al, 2004). However, there are
many open questions on the mechanisms
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and specifically how intracellular Ab impairs
cellular functions leading to neuronal impair-
ment.
One possibility is that Ab accumulation
via the outer membrane transporter (TOM)
affects mitochondrial functions not only by
blocking the entry of other cytosolic proteins
but also by interfering with multiple
processes including oxidative phosphoryla-
tion, reactive oxygen species (ROS)
production, mitochondrial dynamics and
interaction with other mitochondrial
proteins (Pagani & Eckert, 2011). Further-
more, Ab was mainly associated with
synaptic mitochondria in the cortical
neurons of APP/Ab mice, highlighting the
importance of mitochondrial dysfunction in
AD (Du et al, 2010).
The work by Brunetti et al (2015) in this
issue of EMBO Molecular Medicine provides
a novel link between Ab accumulation and
mitochondria. Intracellular degradation of
Ab is performed by two enzymes of the
pitrilysin oligopeptidase family: the human
insulin-degrading enzyme (IDE) and a
mitochondrial-specific pitrilysin metallopep-
tidase 1 (PITRM1), which also digests the
mitochondrial targeting sequences (MTS) of
imported proteins across the inner mito-
chondrial membrane (Falkevall et al, 2006).
Decreased PITRM1 proteolytic activity
contributes to Ab accumulation in the mito-
chondria, leading to neuronal death that is
exacerbated in AD (Alikhani et al, 2011).
Brunetti et al (2015) now identify a
homozygous PITRM1 mutation (c.548G>A,
p.Arg183Gln) in two siblings from an
isolated population in Norway, presenting
with mild intellectual disability, spinocere-
bellar ataxia, cognitive decline and
psychosis by homozygosity mapping and
whole exome sequencing. In support of the
pathogenic role of the mutation, the
authors performed a meticulous set of
experiments including clinical investiga-
tions, studies in fibroblasts and skeletal
muscle of patients and validating the
results in a yeast model and in Pitrm1+/
mice. The clinical picture of the patients
was unusual for mitochondrial disease with
ataxia, cognitive and psychiatric problems
from childhood, showing very slow
progression until their late sixties. Brain
imaging revealed cerebellar and mild cere-
bral atrophy and unilateral signal changes
in the thalamus in one of the siblings.
Biochemical activities of all respiratory
chain enzymes, as well as citrate synthase,
were decreased. The homozygous missense
mutation resulted in decreased level of the
PITRM1 protein, severe growth defect in
galactose medium and decreased mitochon-
drial membrane potential in patient fibro-
blasts. The authors modelled the mutation
in Saccharomyces cerevisiae (cym1R163Q),
which provided convincing evidence that
the mutation resulted in the incomplete
digestion of Ab in the mitochondria.
Finally, heterozygous Pitrm1+/ mice repli-
cated several neurological symptoms seen
in patients and showed an age-dependent
Ab accumulation in the brain, similar to
AD amyloid plaques. Furthermore, impaired
Pitrm1 activity in Pitrm1+/ mice led to the
mitochondrial accumulation of MTS species
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Figure 1. Impaired amyloid-b (Ab) degradation due to the decreased activity of pitrilysin metallopeptidase 1 (PITRM1) contributes to Ab accumulation in the
mitochondria, leading to neuronal death.
The presence of Ab within the mitochondria affects several aspects of mitochondrial function. Interaction of Ab with the outer mitochondrial membrane (OMM) impairs the
transport of nuclear-encodedmitochondrial proteins, such as subunits of the respiratory chain complexes, into the organelle via the translocase of the outermembrane (TOM)
import machinery. Insufficient PITRM1 impairs the degradation of mitochondrial targeting sequences (MTS) cleaved from the imported proteins by the mitochondrial
processing peptidase (MPP), further disturbing the import of proteins into the mitochondria. Respiratory chain dysfunction leads to decreased ATP synthesis in addition to
increased reactive oxygen species (ROS) production. Finally, Ab reduces proton translocation from the matrix to the intermembrane space, thus impairing the mitochondrial
membrane potential (MMP).
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affecting the maturation and function of
imported mitochondria proteins.
The data demonstrate that partial
impairment of the metallopeptidase PITRM1
within the mitochondria causes a novel
mitochondrial disease with neurodegenera-
tion, which is associated with the accumu-
lation of APP and Ab1–42, directly linking
abnormal mitochondrial proteostasis with
Ab accumulation (Fig 1). However, there
are some limitations of the study, since Ab
deposition has been shown in a mouse
model, but not in the patients with mutant
PITRM1, and additional patients with simi-
lar clinical presentation and a different
mutation in the same gene are still lacking.
Identification of variants in PITRM1 or its
mitochondrial interacting partners within
AD cohorts may further strengthen the link
between mitochondria and neurodegenera-
tion. Exploring the pathology of cortical
neurons in patients with various mitochon-
drial diseases and in ageing may identify
further roles of mitochondria in cognition.
Characterization of the molecular mecha-
nism of mitochondrial dysfunction in
neuronal cell death will likely have
further implications for our understanding
of the pathophysiology and designing
treatment for adult-onset neurodegenerative
conditions.
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